Kinase inhibitors for the treatment of inflammatory and autoimmune disorders

被引：39

作者：

Bhagwat, Shripad S. ^{[1
]}

机构：

[1] Ambit Biosci, San Diego, CA 92121 USA

来源：

PURINERGIC SIGNALLING | 2009年 / 5卷 / 01期

关键词：

Kinase inhibitors; Anti-inflammatory agents; Autoimmune modulators; IKK2; inhibitors; Syk inhibitors; Lck inhibitors; JAK3; KAPPA-B KINASE; IKK-BETA INHIBITORS; POTENT; DISCOVERY; SYK; JAK3; LCK; SAR; DERIVATIVES; BMS-345541;

D O I：

10.1007/s11302-008-9117-z

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Drugs targeting inhibition of kinases for the treatment of inflammation and autoimmune disorders have become a major focus in the pharmaceutical and biotech industry. Multiple kinases from different pathways have been the targets of interest in this endeavor. This review describes some of the recent developments in the search for inhibitors of IKK2, Syk, Lck, and JAK3 kinases. It is anticipated that some of these compounds or newer inhibitors of these kinases will be approved for the treatment of rheumatoid arthritis, psoriasis, organ transplantation, and other autoimmune diseases.

引用

页码：107 / 115

页数：9

共 50 条

[21] An updated research of glycogen synthase kinase-3β inhibitors: a review
Liu, Shan-Kui
Xie, Hong-Xu
Ge, Yong-Xi
Zhang, Juan
Jiang, Cheng-Shi
MONATSHEFTE FUR CHEMIE, 2021, 152 (01): : 19 - 33
[22] Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease
Barker, Michael D.
Liddle, John
Atkinson, Francis L.
Wilson, David Matthew
Dickson, Marion C.
Ramirez-Molina, Cesar
Lewis, Huw
Davis, Rob P.
Somers, Donald O.
Neu, Margarete
Jones, Emma
Watson, Robert
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (21) : 3458 - 3462
[23] Developments of Fms-like Tyrosine Kinase 3 Inhibitors as Anticancer Agents for AML Treatment
Ma, Chenchen
Cui, Siyuan
Xu, Ruirong
CURRENT MEDICINAL CHEMISTRY, 2024, 31 (29) : 4657 - 4686
[24] The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease
De Vries, L. C. S.
Wildenberg, M. E.
De Jonge, W. J.
D'Haens, G. R.
JOURNAL OF CROHNS & COLITIS, 2017, 11 (07) : 885 - 893
[25] Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment
Takahashi, Shinichiro
HEMATOLOGY REPORTS, 2023, 15 (02) : 331 - 346
[26] Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases
Cetkovic-Cvrlje, M
Uckun, FM
ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2004, 52 (02) : 69 - 82
[27] B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies
Puri, Kamal D.
Di Paolo, Julie A.
Gold, Michael R.
INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2013, 32 (04) : 397 - 427
[28] Immunomodulatory role of spleen tyrosine kinase in chronic inflammatory and autoimmune diseases
Zhou, Yaqi
Zhang, Yaowen
Yu, Wei
Qin, Yufen
He, Heng
Dai, Fengxian
Wang, Yibo
Zhu, Fengqin
Zhou, Guangxi
IMMUNITY INFLAMMATION AND DISEASE, 2023, 11 (07)
[29] Upadacitinib tartrate Tyrosine-protein kinase JAK1 inhibitor Treatment of autoimmune inflammatory diseases Treatment of rheumatoid arthritis
Gajdosik, Z.
DRUGS OF THE FUTURE, 2018, 43 (10) : 731 - 743
[30] Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases
Perry, Matthew W. D.
Abdulai, Raolat
Mogemark, Mickael
Petersen, Jens
Thomas, Matthew J.
Valastro, Barbara
Eriksson, Annika Westin
JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (10) : 4783 - 4814

← 1 2 3 4 5 →